Similarly, Mazzachi et al. [104] observed a two-fold increase in the percentage of and absolute number of PD-1+ CD8+ lymphocytes in patients with non-small cell lung cancer who derived clinical benefit, compared to those who did not from the use of nivolumab therapy [104]. Here, RPL17 is linked to non-small cell lung carcinoma.